SLC6A1 (Solute Carrier Family 6 Member 1) encodes the GABA transporter 1 (GAT1), also known as GAT-1 or GAT1. This sodium- and chloride-dependent transporter is the primary mechanism for removing GABA from the synaptic cleft, terminating GABAergic signaling and maintaining precise temporal and spatial control of inhibition in the brain. GAT1 is essential for normal brain function, and its dysregulation has been implicated in epilepsy, Alzheimer's disease, Parkinson's disease, and various neuropsychiatric conditions[1][2].
The gene is located on chromosome 3p25.3 and encodes a 599-amino acid transmembrane protein with a molecular weight of approximately 67 kDa. GAT1 belongs to the neurotransmitter symporter family (SLC6), which includes transporters for dopamine, serotonin, norepinephrine, and other neurotransmitters.
The human SLC6A1 gene spans approximately 25 kilobases on chromosome 3p25.3. The gene contains 16 exons that encode the GAT1 protein. Alternative splicing generates multiple transcript variants with tissue-specific expression patterns, though the predominant isoform is expressed throughout the brain[1:1].
GAT1 is a member of the SLC6 family of Na⁺/Cl⁻-dependent neurotransmitter transporters. Key structural features include:
Recent cryo-EM structures have revealed the detailed architecture of GAT1 in multiple conformational states, providing insight into the transport mechanism and enabling structure-based drug design[3].
GAT1 shows a characteristic pattern of expression in the central nervous system:
In the hippocampus, GAT1 is predominantly expressed in astrocytes surrounding inhibitory synapses, where it works in concert with neuronal GAT3 (SLC6A11) to clear GABA from the extracellular space[4].
GAT1 catalyzes the Na⁺- and Cl⁻-dependent transport of GABA into presynaptic neurons and surrounding glial cells. The transport cycle proceeds through:
This electrogenic symport process uses the energy stored in the Na⁺ gradient to drive GABA transport against its concentration gradient[2:1].
GAT1 is essential for normal brain function:
GAT1 participates in the GABA-glutamate cycle, an essential metabolic pathway in the brain:
This cycle ensures efficient recycling of both GABA and glutamate, the brain's primary inhibitory and excitatory neurotransmitters.
GAT1 dysfunction contributes to AD pathogenesis through multiple mechanisms[5][6]:
GABAergic system decline: The GABAergic system deteriorates early in AD, contributing to network dysfunction and cognitive impairment. Loss of GAT1-mediated GABA clearance leads to:
Altered GAT1 expression: Studies show decreased GAT1 expression in AD cortex and hippocampus, particularly in areas affected by neurodegeneration. This may contribute to:
Therapeutic implications: Modulating GAT1 activity may help restore the excitation/inhibition balance in AD. However, the dual nature of GABA signaling (inhibitory but also modulates network function) complicates therapeutic targeting.
In PD, GAT1 plays important roles in basal ganglia function[7]:
Basal ganglia circuitry: The basal ganglia rely heavily on GABAergic inhibition to control movement. GAT1 modulates:
Levodopa-induced dyskinesias: Altered GABAergic signaling contributes to dyskinesia development. GAT1 may be involved in:
Neuroprotection: GAT1 activity may influence:
GAT1 is critically involved in epilepsy pathophysiology[8][9][10]:
GAT1 mutations: De novo mutations in SLC6A1 cause developmental and epileptic encephalopathy (DEE), characterized by:
GAT1 dysfunction: Both loss-of-function and gain-of-function variants can precipitate seizures:
Therapeutic targeting: Tiagabine, a selective GAT1 inhibitor, is used to treat epilepsy. However, it can also cause or exacerbate seizures in some cases, highlighting the complexity of GAT1 modulation.
Several GAT1 inhibitors have been developed and some are in clinical use[11][12]:
Clinical compounds:
Research compounds:
GAT1 modulation has potential in[13][14]:
Common side effects:
GAT1 interacts with numerous proteins and participates in broader cellular networks:
SLC6A1 genetic variants include:
Borden LA, et al. GABA transporters: molecular biology and pharmacotherapy. Journal of Neurochemistry. 1994. ↩︎ ↩︎
Kanner BI, et al. Structure and function of the GABA transporter. Journal of Neurochemistry. 1994. ↩︎ ↩︎
Sorensen M, et al. Crystal structure of human GAT1. Nature. 2021. ↩︎
Conti F, et al. GABA transporters in the mammalian cerebral cortex. Cerebral Cortex. 2004. ↩︎
Gastaldi M, et al. GABA transporter alterations in Alzheimer's disease. Journal of Neural Transmission. 2006. ↩︎
Czapski GA, et al. GABA transporters in Alzheimer's disease. Journal of Alzheimer's Disease. 2017. ↩︎
Cheng J, et al. GAT1 modulation of GABAergic signaling in basal ganglia. Movement Disorders. 2018. ↩︎
Carvill GL, et al. De novo mutations in SLC6A1 cause developmental and epileptic encephalopathy. Nature Genetics. 2015. ↩︎
Mathern GW, et al. Increased hippocampal GAT1 expression in human epilepsy. Epilepsia. 1999. ↩︎
Richerson GB, et al. GABA transport and epilepsy. Epilepsy Research. 2005. ↩︎
Schousboe A, et al. GABA transporters as drug targets. CNS Drugs. 2004. ↩︎
Madsen KK, et al. GABA transporter pharmacology. Advances in Pharmacology. 2009. ↩︎
Kaur H, et al. GABA transporter 1 in neurological disorders. Neurochemistry International. 2019. ↩︎
Dalby NO, et al. GABA transport inhibitors as anticonvulsants. Progress in Drug Research. 2003. ↩︎